

Quarterly pharmacy formulary change notice

Summary: The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018, Pharmacy and Therapeutics Committee meeting.

Effective August 1, 2018, the changes outlined below apply to all HealthChoice members.

| Effective for all patients on August 1, 2018 | | | |
|--|---|---|---|
| Therapeutic class | Drug | Revised status | Potential alternatives |
| INSULIN | APIDRA 100 UNITS/ML VIAL APIDRA SOLOSTAR 100 UNITS/ML | NONPREFERRED EFFECTIVE FOR NEW STARTS ON 8/1/18; EFFECTIVE FOR CURRENT UTILIZERS ON 10/1/18 | ADMELOG 100 UNIT/ML VIAL ADMELOG SOLOSTAR 100 UNIT/ML |
| INSULIN | ADMELOG 100 UNIT/ML VIAL ADMELOG SOLOSTAR 100 UNIT/ML | PREFERRED ADD QL 30MLS PER 30 DAYS | N/A |
| INSULIN (EDIT ONLY) | HUMULIN R 500 UNITS/ML VIAL HUMULIN R 500 UNITS/ML KWIKPEN | ADDING PA TO PREFERRED PRODUCT | N/A |
| ANTIPERSPIRANTS | HYPERCARE 15% SOLUTION | PREFERRED | N/A |
| DPP4s | JENTADUETO 2.5 MG-1000 MG TAB JENTADUETO 2.5 MG-500 MG TAB JENTADUETO 2.5 MG-850 MG TAB JENTADUETO XR 2.5 MG-1,000 MG JENTADUETO XR 5 MG-1,000 MG TB TRADJENTA 5 MG TABLET | NONPREFERRED | JANUVIA JANUMET XR ST APPLIES |
| GLP1s | TANZEUM 30 MG PEN INJECT TANZEUM 50 MG PEN INJECT | NONPREFERRED | OZEMPIC VICTOZA ST APPLIES |
| GLP1s | OZEMPIC 0.25-0.5 MG DOSE PEN OZEMPIC 1 MG DOSE PEN | PREFERRED WITH STEP THERAPY EFFECTIVE 4/1/18 | N/A |
| ICS/LABA | (AUTHORIZED GENERIC OF AIRDUO RESPICLICK) FLUTICASONE-SALMETEROL 55-14 FLUTICASONE-SALMETEROL 113-14 FLUTICASONE-SALMETEROL 232-14 | PREFERRED | N/A |
| ICS/LABA | DULERA 100 MCG/5 MCG INHALER DULERA 200 MCG/5 MCG INHALER | NONPREFERRED CURRENT UTILIZERS WILL BE GRANDFATHERED | *AUTHORIZED GENERIC FOR AIRDUO RESPICLK FLUTICASONE- SALMETEROL BREO ELLITA |

| | | | |
|--|--|--|---|
| IRON SUPPLEMENTS | POLY-VI-SOL WITH IRON DROPS POLY-VI-SOL DROPS | PREFERRED | N/A |
| MISCELLANEOUS ANTINEOPLASTIC DRUGS | MITOXANTRONE 20 MG/10 ML VIAL MITOXANTRONE 25 MG/12.5 ML VL MITOXANTRONE 30 MG/15 ML VIAL | COVERED | N/A |
| MISCELLANEOUS OPHTHALMOLOGICS | VISUDYNE 15 MG VIAL | COVERED | N/A |
| IMMUNOMODULATORS | PROLEUKIN 22 MILLION UNIT VIAL | NONPREFERRED ADD PA | N/A |
| LAMA/LABA | STIOLTO RESPIMAT INHAL SPRAY | PREFERRED | N/A |
| PHOSPHATE BINDERS | LANTHANUM CARB 500 MG TAB CHEW LANTHANUM CARB 750 MG TAB CHEW LANTHANUM CARB 1,000 MG TB CHW SEVELAMER 0.8 GM POWDER PACKET SEVELAMER 2.4 GM POWDER PACKET SEVELAMER CARBONATE 800 MG TAB | PREFERRED WITH PA | N/A |
| PHOSPHATE BINDERS | VELPHORO 500 MG CHEWABLE TAB | NONPREFERRED CURRENT UTILIZERS WILL BE GRANDFATHERED | ELIPHOS 667 MG TABLET CALCIUM ACETATE 667 MG LANTHANUM CHEW TAB SEVELAMER TAB/PACKET |
| PRENATAL VITAMINS | GENERIC OTC PRODUCTS ONLY | PREFERRED | N/A |
| PRENATAL VITAMINS | BRAND OTC ALL RX PRODUCTS | NONPREFERRED CURRENT UTILIZERS WILL BE GRANDFATHERED | GENERIC OTC PRENATALS |
| EDITS | | | |
| <i>No changes in preferred/nonpreferred status revision or addition to UM edit only.</i> | | | |
| ANTIBIOTICS | BAXDELA 450 MG TABLET | ADD QL 28 TABLETS PER FILL; 1 FILL PER 30 DAYS | |
| COUGH AND COLD | COUGH AND COLD PRODUCTS CONTAINING HYDROCODONE | ADD AL MEMBERS EQUAL TO OR LESS THAN 18 REQUIRE PA | |
| COUGH AND COLD | COUGH AND COLD PRODUCTS CONTAINING CODEINE | ADD AL MEMBERS EQUAL TO OR LESS THAN 18 REQUIRE PA | |
| ANTIVIRALS | PREVYMIS 240 MG/12 ML VIAL PREVYMIS 480 MG/24 ML VIAL | ADD QL 1 VIAL PER DAY 100 DAYS OF TREATMENT | |
| ANTIVIRALS | PREVYMIS 240 MG TABLET PREVYMIS 480 MG TABLET | ADD QL 1 TABLET PER DAY 100 DAYS OF TREATMENT | |
| ASTHMA | XOPENEX 30 VIALS | 90 VIALS PER 30 DAYS | |

| | | |
|--|---|---|
| BILE ACIDS | CHENODAL 250 MG TABLET | ADD QL 7 TABLETS PER DAY |
| CANCER AGENTS | ALUNBRIG 180 MG TABLET | ADD QL 1 TABLET PER DAY |
| CANCER AGENTS | ALUNBRIG 90 MG-180 MG TAB PACK | ADD QL 1 PACK IN 30 DAYS |
| CANCER AGENTS | ALUNBRIG 90 MG TABLET | REVISED QL 2 TABLETS DAILY |
| CONSTIPATION AGENTS | SYMPROIC 0.2 MG TABLET | ADD QL 1 TABLET PER DAY |
| COPD | BROVANA 15 MCG/2 ML SOLUTION | ADD QL 2 VIALS (4ML) PER DAY |
| COPD | PERFOROMIST 20 MCG/2 ML SOLN | ADD QL 2 VIALS (4ML) PER DAY |
| COPD | LONHALA MAGNAIR 25 MCG STARTER | ADD QL 1 KIT PER 30 DAYS |
| COPD | LONHALA MAGNAIR 25 MCG REFILL | ADD QL 1 PER 30 DAYS |
| GLP-1 RECEPTOR AGONIST | OZEMPIC 0.25-0.5 MG DOSE PEN | ADD QL 1 PEN PER 28 DAYS |
| GLP-1 RECEPTOR AGONIST | OZEMPIC 1 MG DOSE PEN | ADD QL 2 PENS PER 28 DAYS |
| HEPATITIS C TREATMENT AGENTS | PEGINTRON 50 MCG KIT PEGASYS 180 MCG/0.5 ML SYRINGE PEGASYS 180 MCG/ML VIAL PEGASYS PROCLICK 180 MCG/0.5 PEGASYS PROCLICK 135 MCG/0.5 | REMOVE PA |
| ICS | QVAR REDHALER 40 MCG | ADD QL 1 INHALER PER 30 DAYS |
| ICS | QVAR REDHALER 80 MCG | ADD QL 2 INHALERS PER 30 DAYS |
| LIPID/CHOLESTEROL LOWERING AGENTS | FLOLIPID | ADD QL 5MLS PER DAY |
| PANCREATIC ENZYMES | PERTZYE DR 24;000 UNIT CAPSULE | ADD QL 25 CAPSULES PER DAY |
| PANCREATIC ENZYMES | VIOKASE | ADD QL 25 TABLETS PER DAY |
| POTASSIUM SPARING DIURETICS | CAROSPIR 25 MG/5 ML SUSPENSION | ADD PA AND QL 20ML PER DAY |
| PROGESTINS | CRINONE 4% GEL CRINONE 8% GEL | ADD QL 1 APPLICATORFUL PER DAY |
| PULMONARY ARTERIAL HYPERTENSION | TRACLEER 32 MG TABLET FOR SUSP | ADD QL 32 MG TABS FOR SUSP – 4 TABLETS PER DAY |
| SGLT2 | XIGDUO XR 2.5 MG-1;000 MG TAB | ADD QL 2 TABLETS PER DAY |

| | | |
|------------------------------|--|-------------------------------|
| SGLT2 | STEGLATRO 5 MG TABLET STEGLATRO 15 MG TABLET | ADD QL 1 TABLET PER DAY |
| SGLT2 | SEGLUROMET 7.5-1;000 MG TABLET SEGLUROMET 2.5-500 MG TABLET SEGLUROMET 7.5-500 MG TABLET SEGLUROMET 2.5-1;000 MG TABLET | ADD QL 2 TABLETS PER DAY |
| SGLT2/DPP-4 INHIBITOR | STEGLUJAN 5-100 MG TABLET STEGLUJAN 15-100 MG TABLET | ADD QL 1 TABLET PER DAY |
| TOPICAL ANTIFUNGALS | LOPROX 0.77% CREAM | ADD QL 90 GMS PER 30 DAYS |
| TOPICAL ANTIFUNGALS | LOTRIMIN ULTRA 1% CREAM | ADD QL 30 GMS PER 30 DAYS |
| TOPICAL ANTIFUNGALS | NYSTATIN 100;000 UNIT/GM CREAM NYSTATIN 100;000 UNITS/GM OINT KETOCONAZOLE 2% CREAM | ADD QL 120 GMS PER 30 DAYS |
| TOPICAL ANTIFUNGALS | OXISTAT 1% CREAM | ADD QL 60 GMS PER 30 DAYS |

What action do I need to take?

Please review these changes and work with your patients to transition them to formulary alternatives. If you determine preferred formulary alternatives are not clinically appropriate for specific patients, you will need to obtain prior authorization (PA) to continue coverage beyond the applicable effective date.

What if I need assistance?

We recognize the unique aspects of patients' cases. If for medical reasons your patient cannot be converted to a formulary alternative, call our Pharmacy department at 1-800-454-3730 and follow the voice prompts for pharmacy PA. You can find the *Preferred Drug List* on our provider website at <https://providers.amerigroup.com>.

If you need assistance with any other item, contact your local Provider Relations representative or call Provider Services at 1-800-454-3730.